罗氏诊断苏州十周年，续写“中国智造”新篇章

Core Insights - Roche Diagnostics is celebrating the 10th anniversary of its Suzhou operations, emphasizing its commitment to the Chinese market and the enhancement of its R&D and manufacturing capabilities [1][2]. Group 1: Investment and Expansion - Roche Diagnostics has made significant investments in Suzhou, including the establishment of the Asia-Pacific production base in 2015, the launch of the Asia-Pacific R&D center in 2018, and the construction of a reagent manufacturing base in 2020 [1]. - A new investment project in Suzhou has been signed, which is the largest single investment by Roche in China, with construction expected to begin in 2025 and production slated for 2028, covering over 400 types of reagents and instruments [1]. Group 2: Innovation and Product Development - Over the past decade, Roche has strengthened its local innovation, R&D, and production capabilities, successfully launching several domestic in vitro diagnostic products, including reagents and instruments [2]. - The Suzhou base maintains the same standards for production processes, technology, raw materials, and formulations as Roche's original factories, ensuring that "Made in China" products meet global quality benchmarks [3]. Group 3: Strategic Commitment - Roche Diagnostics has been operating in China for 25 years, adhering to its core strategy of "In China, For China," and aims to accelerate the localization process and expand its product pipeline [3].